应用ARMS- PCR法检测非小细胞肺癌EGFR基因突变及其临床意义  

The Detection of EGFR Gene Mutation in Non- small Cell Lung Cancer Using ARMS- PCR and Its Clinical Significance

作　　者：周怡[1] 陆明洋[1] 王琦[1] 郑晓[1] 孙青[1] ZHOU Yi;LU Mingyang;WANG Qi;ZHENG Xiao;SUN Qing(Department of Tumor Biological Treatment,the Third Affiliated Hospital of Soochow University,Changzhou 213003,China)

机构地区：[1]苏州大学附属第三医院肿瘤生物诊疗中心,江苏常州213003

出　　处：《标记免疫分析与临床》2020年第7期1166-1168,共3页Labeled Immunoassays and Clinical Medicine

基　　金：国家自然科学基金青年基金项目(编号:81902386);常州市应用基础研究项目(编号:CJ20160021,CJ20179048);江苏省检验医学重点实验室开放基金(编号:JSKLM-2014-003)。

摘　　要：目的探讨依据ARMS法原理,采用实时荧光定量PCR法检测非小细胞肺癌EGFR基因突变的可行性并分析检测的临床意义。方法收集苏州大学附属第三医院2010年9月至2011年12月确诊为NSCLC患者标本64例,DNA提取后,采用ARMS-PCR法对标本进行EGFR基因突变检测并分析EGFR基因突变与患者临床病理参数的关系。结果本研究发现64例NSCLC患者的EGFR总突变率为23.4%,均为19号外显子缺失(19-Del)和21号外显子(L858R)突变;女性EGFR突变率高于男性,腺癌高于鳞状细胞癌。结论 EGFR基因突变检测有助于规范表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)在NSCLC患者中的临床应用。Objective This work intends to investigate the feasibility of real-time quantitative PCR in detecting EGFR gene mutation in non-small cell lung cancer based on the principle of ARMS. It is also aimed to analyze the clinical significance of the detection.Methods Sixty-four patient specimens with NSCLC were collected in the Third Affiliated Hospital of Soochow University from September, 2010 to December, 2011. After DNA extraction, the EGFR gene mutation was detected by ARMS-PCR. Furthermore, the relationship between EGFR gene mutation and clinical pathological features was analyzed.Results It was found that 64 patients with NSCLC had a total EGFR mutation rate of 23.4%, all of which were exon 19 deletion(19-Del) and exon 21(L858 R) mutation. Female EGFR mutation rate was higher than male. Adenocarcinoma was higher than squamous cell carcinoma.Conclusion EGFR gene mutation detection contributes to regulating the clinical application of epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI) in patients with NSCLC.

关 键 词：表皮生长因子受体 基因突变 肺癌 表皮生长因子受体酪氨酸激酶抑制剂 探针扩增阻碍突变系统PCR法 

分 类 号：Q344.12[生物学—遗传学] R734.2[医药卫生—肿瘤]